Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

CHMP backs updated Pfizer/BioNTech and Moderna COVID-19 boosters

By Brian Buntz | September 2, 2022

COVID-19 vaccine

[Image courtesy of Pixabay.]

EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended authorizing bivalent COVID-19 vaccines from Pfizer/BioNTech and Moderna.

The boosters target the omicron BA.1 sublineage.

Assuming the European Commission follows CHMP’s recommendations, the European vaccine campaign will use bivalent vaccines targeting the original version of the omicron variant.

U.S. regulators, by contrast, have backed the use of bivalent vaccine boosters that target the BA.4/BA.5 sublineages of omicron. While Pfizer/BioNTech (NYSE:/PFE, Nasdaq: BNTX) and Moderna (Nasdaq:MRNA) have both developed vaccine boosters based on BA.4/BA.5, there is currently no human data for those vaccines. Instead, FDA is relying on data from earlier vaccine versions and preclinical data.

EMA’s recommended that the updated boosters be used in individuals at least 12 years of age who have received at least two doses of COVID-19 vaccines.

The updated COVID-19 vaccine boosters are likely to have superior protection against omicron.

European regulators note that side effects associated with the updated vaccines were comparable to those associated with the original versions.

EU aims to make “a broad range of adapted vaccines” available to target various SARS-CoV-2 variants.

European regulators could also authorize boosters targeting the BA.4 and BA.5 omicron subvariants.

In reviewing the bivalent Comirnaty vaccine from Pfizer and BioNTech targeting BA.1 and the original coronavirus, CHMP reviewed data from two studies. One of those trials focused on adults 55 and older who had previously received three doses of Comirnaty before receiving the adapted booster. The immune response was superior for the BA.1 subvariant and comparable for the original SARS-CoV-2 strain.

CHMP also considered data from a study with more than 600 people between 18 and 55 who had received three prior doses of Comirnaty. Recipients of a monovalent BA.1 vaccine had a superior immune response than those receiving the original Cormirnaty vaccine.

The organization also reviewed clinical trial data from recipients of Moderna’s updated Spikevax vaccine based on omicron BA.1. The adapted vaccine also induced a more robust immune response than the original Spikevax vaccine.

Authorizing the BA.1-adapted vaccines represents a “quantum leap in the fight against the pandemic,” said German Health Minister Karl Lauterbach. “Now vaccines can be used that work very well against all the known virus variants.”

Pfizer and BioNTech announced in July that they were pursuing authorization of the updated COVID-19 vaccine.

The UK, Switzerland and Australia have also authorized updated COVID-19 vaccines.

 

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

institut pasteur dakar IPD African Union vaccine investment
African Union vaccine initiative receives $45M
Sen-Jam Pharma, KVK-Tech partnering for manufacturing and formulation for anti-inflammatory injectables
This image shows the Moderna logo.
Moderna resizes its manufacturing footprint for a post-pandemic era
This is the logo of Pfizer.
Pfizer to close Durham and Morrisville, North Carolina facilities amid major restructuring effort
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE